Articles related to GUIDELINES/RECOMMENDATIONS

Key practice-changing points from the latest guidelines: • 1st line therapy is sacubitril plus valsartan, as this combination increases survival and reduces hospitalizations versus ACE inhibitors and ARBs.• ACE inhibitors should be used only in patients who cannot tolerate sacubitril-valsartan, and ARBs used only in those who cannot tolerate either the 1st- or 2nd-line recommended therapies.• Patients whose ejection fraction increases to more than 40% under therapy should continue to receive therapy.

Per the Standards, “diabetes management in older adults requires regular assessment of medical, psychological, functional, and social domains. Older adults with diabetes have higher rates of premature death, functional disability, accelerated muscle loss, and coexisting illnesses … and … are also at greater risk for several common geriatric syndromes, such as polypharmacy, cognitive impairment, depression, urinary incontinence, injurious falls, persistent pain, and frailty. All these can impair their self-management.”

A clear synopsis of the McDonald criteria, including application of the criteria with different manifestations of MS. This overview also provides an FAQ and the features the criteria in tabular and chart formats.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?

The smartwatch market generated approximately 38.6 billion US dollars in revenue globally in 2022, and growth is expected to continue. Over a hundred of these devices, ranging from AI ultrasounds to smart sleep trackers and ECG watches, have been tried and tested by the author. His “7+1” recommendations are listed here.

The update was based on the findings of 31 systematic reviews and 16 randomized controlled trials (RCTs) chosen from a total of 820 publications. The investigators set out to answer seven questions: